CVS Health Revises FY23 GAAP EPS Guidance To $6.53-$6.75 From $6.90-$7.12, Reaffirms Adjusted EPS Guidance Of $8.50-$8.70 Vs. Consensus Of $8.59.
Portfolio Pulse from Benzinga Newsdesk
CVS Health has revised its FY23 GAAP EPS guidance to $6.53-$6.75 from $6.90-$7.12, but reaffirmed its adjusted EPS guidance of $8.50-$8.70, which is in line with the consensus of $8.59.
August 04, 2023 | 11:18 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CVS Health has lowered its FY23 GAAP EPS guidance, which could potentially impact investor sentiment and the company's stock price.
CVS Health's revision of its FY23 GAAP EPS guidance to a lower range may negatively impact investor sentiment as it indicates potentially lower profitability. However, the company's reaffirmation of its adjusted EPS guidance, which is in line with consensus, may mitigate some of this negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100